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doi:10.1016/j.fjs.2012.03.005Summary Tumor with bone metastases to the periacetabulum is rare, and its surgical
management is challenging. Instead of wide excision with reconstruction of the hip joint,
we used a relatively noninvasive method to manage periacetabular metastasis. Such a proce-
dure for this condition has the benefits of short surgical time, less bleeding, and fewer
complications during surgery. Our surgical management of the case reported here included
curettage, phenol cauterization and filling of cisplatin-loaded cement in order to reduce
local recurrence. After following-up for 2 years, there was no local recurrence and disease
progression.
Copyright ª 2012, Taiwan Surgical Association. Published by Elsevier Taiwan LLC. All rights
reserved.1. Introduction
Bone destruction in the acetabulum by metastatic tumor
will cause hip pain and limitation of weightbearing. Har-
rington and colleagues1 showed that hip reconstruction
for periacetabular metastasis could improve functional
status and reduce pain. The treatment of acetabular boneDepartment, Taipei Veterans
Shih-Pai Road, Taipei 112,
ov.tw (W.-M. Chen).
ight ª 2012, Taiwan Surgical Assometastases presents numerous clinical challenges including
the necessity for careful patient selection for surgery,
determination of the extent of bone destruction, and
providing the patient with stable surgical reconstruction of
the pelvis. According to the system of Enneking and Dun-
ham,2 pelvic resection for malignancy can be sorted out
into three types by region: iliac wing resections (Type I),
periacetabular resections (Type II), and anterior arch
resections (Type III). After the publication of papers on
wide periacetabular excision, several surgical methods
were reported for reconstruction such as by recycled ilio-
femoral and ischiofemoral arthrodesis, acetabulum allo-
graft, or saddle prosthesis.3ciation. Published by Elsevier Taiwan LLC. All rights reserved.
128 Y.-C. Chen et al.Recently, we successfully treated a case of synchronous
primary cancer of the ovary and that of the endometrium
with acetabular metastasis with a newly developed cisplatin-
loaded cement support surgery. Instead of wide excision
and reconstruction of the hip, we filled the tumor lesion
with cisplatin-loaded cement after curettage. After a 2-year
follow-up, there was no local recurrence at or around
the acetabulum. The hip joint was preserved with intact
function.Figure 1 Bony expansile lytic lesion in the right peri-
acetabular area.
Figure 2 Suspected bony metastasis in the right peri-
acetabular region.2. Case report
A premenopausal woman aged 39 years presented to a local
gynecologist with chief complaints of abnormal vaginal
bleeding and abdominal discomfort for 1 month. There was
no body weight loss, poor appetite, or dysmenorrhea. A
transvaginal ultrasound was performed that revealed
a right adnexal mass. The tentative diagnosis of ovarian
cyst was made, and laparoscopic salpingo-oophorectomy on
the right side was performed. During the operation, rupture
of the right ovary with fluid accumulation at the cul-de-sac
was noted and the histopathology reported serous adeno-
carcinoma of the right ovary. The patient was subsequently
transferred to our hospital for further evaluation and
management. No distant metastasis was found by an image
study. Based on ovarian cancer with incomplete surgery,
optimal debulking surgery was done, including hysterec-
tomy, bilateral oophorotomy, salpingectomy, pelvic lymph
node, para-aortic lymph node sampling, omentectomy
and appendectomy. Grossly, residual tumor masses were
completely removed from the cul-de-sac, uterovesical
pouch, sigmoid, and transverse colon. The histopathology
report showed endometrioid adenocarcinoma of the endo-
metrium and left ovary with invasion into the uterine
myometrium (< 1/2) and metastatic adenocarcinoma in
the right pelvic wall, colon, and para-aortic lymph nodes.
The cervix, fallopian tubes, and omentum were tumor-free.
The patient was staged as having endometrial adenocarci-
noma stage IC, Grade 2, and ovarian serous carcinoma,
Stage IIIC. She was advised to receive adjuvant chemo-
therapy after the surgery with the regimens of Taxol
(260 mg) and Abiplatin (110 mg).
Progressive right hip pain was complained of after the
debulking surgery. The patient was able to ambulate but
required an assistant device, especially at night. However,
she did not pay attention to the pain at first. After nine
courses of chemotherapy with a 3-week interval, the pelvic
plain film revealed a suspicious lytic, expansile bony lesion
(Fig. 1). The follow-up computed tomography (CT) scan
indicated bony metastasis at the right periacetabular
region (Fig. 2). CT-guided biopsy was performed, and the
histopathologic examination reported metastatic tumor,
well-differentiated adenocarcinoma. A whole-body bone
scan disclosed bone metastasis to the right periacetabular
region without other metastasis. Considering her age,
performance status, and quality of life, palliative surgery
was suggested mainly to relieve pain.
In evaluation of the tumor, magnetic resonance imaging
examination was performed before surgery and showed
a mass of about 3 cm in diameter without joint space
involvement (Fig. 3). This was considered to bea periacetabular metastatic tumor, which required wide
excision including hip joint. However, the patient had
undergone major gynecologic surgery and series of chemo-
therapy within 6 months, which made her weak and
depressed, probably unsuitable for further major surgeries.
After discussion with the patient, she agreed to undergo
intralesional curettage with hip preservation, instead of
a Type II resection of the pelvic bone. In a lateral position,
the operation was performed through a posterolateral
approach with a wound about 10 centimeters in length. At
the lateral side of the acetabulum, we made a burr hole of
2 cm in diameter and executed adequate intralesional
Figure 3 Metastatic tumor in the right periacetabular area.
Figure 4 Postoperative plain film.
Management for periacetabular metastasis 129curettage. The cavity was irrigated with a large amount of
normal saline, and the free margin was cauterized by
phenol. One package of cement (40 mg) (Howmedica,
Mahwah, NJ, USA) was blended with cisplatin (50 mg/
100 ml). As humidity lengthened the setup time from the
liquid to the doughy phase, we added cisplatin drop by drop
with persistent stirring from the liquid phase. The capacity
of 40 mg cement is equivalent to about 30 ml of cisplatin
(50 mg/100 ml). It took 10 minutes to reach the doughy
phase and another 5e7 minutes to the solid phase. The
progress was prolonged and yet smooth. In the doughy
phase, the cisplatin-loaded cement filled the bone cavity
created by curettage of the tumor. The neurovascular
structures were left intact after surgery, without injuring
the articular space. The skin-to-skin operative time was 80
minutes with a blood loss of less than 200 ml.
After the surgery, the pain at the hip was significantly
relieved and, after 2 days, the patient recovered to
complete weightbearing status, free of walking aids. Her
general condition and wound condition were good and she
was discharged on Postoperative Day 4. The adjuvant
radiotherapy for local treatment with the total dose of
45 Gy in 28 fractions began 3 weeks later. Then, she was
reviewed with surveillance radiographs every 3 months in
the following 2 years (Fig. 4). Serial radiographs and
clinical examination showed no signs of recurrence of
disease (Fig. 5A and B). At her last follow-up on May 10,
2011, more than 2 years after the surgery, she had no
residual pain and had a normal gait without the use of
walking aids.
3. Discussion
There are three general principles for surgical treatment of
metastatic bone disease: tumor removal, filling of the
resultant bone defect, and bypass of the defect. For pelvic
tumor, either primary or metastasis, surgical managementis challenging. The complexity of acetabular, pelvic bone
anatomy, and the proximity of neurovascular structures can
complicate the surgery. Type II periacetabular lesions are
particularly difficult to treat, and their reconstruction
results in a high incidence of mechanical complications.
Besides, the reconstruction of the acetabulum is a major
surgical procedure with a significant risk of complications.4
A retrospective review of surgical procedures for peri-
acetabular metastasis shows that the average blood loss
during the operation was 1600 ml in 43 patients and the
bleeding exceeded 3000 ml in three patients with renal
carcinomas.5 The complications of periarticular recon-
struction included deep infections, superficial infections,
wound complications, local recurrence, fracture, disloca-
tions, rotational deformity, and even intraoperative
mortality.6 The study also documented that the complica-
tion rate related to implants was 21.7%.7 A prospective
multicenter study revealed that periacetabular endopros-
thetic replacement was associated with acceptable func-
tional and oncological outcome but a high complication
rate owing, predominantly, to infection.8 The indication for
hemipelvic prosthesis in patients with a metastatic disease
must be considered seriously.
Instead of wide excision with reconstruction, in this case
we designed an intralesional tumor excision to preserve the
structures adjacent to the hip joint. To reduce local recur-
rence, phenol was used to cauterize the tumor margin and
the defect was filled with cisplatin-loaded cement. Schiller
and colleagues9 demonstrated that the recurrence rate was
significantly lowered by using phenol following intralesional
excision of nonmalignant bone tumors. Although there were
no data on phenol management in malignant tumor, we
assume the chemical cauterization effect of phenol is
intended to destroy any remaining tumor cell remnants.
Based on our hypothesis for reducing the local recurrence
rate, phenol was used to cauterize the tumor margin.
Figure 5 Magnetic resonance imaging follow-up on (A) July 7, 2010; and (B) January 23, 2011.
130 Y.-C. Chen et al.In recent years, calcium phosphate biomaterials have
been used as bone drug delivery systems. Previous investi-
gators described the use of bone cement containing anti-
biotics, and satisfactory results have been reported in the
treatment of chronic osteomyelitis and post-operative
infections.10 Recent study confirmed the potential of
antiblastic-loaded cement as a possible adjuvant in the
local treatment of bone metastases.11 There are also
some research studies12,13 that reported no changes in the
stability and metabolic activity of antineoplastic agents
(cisplatin, methotrexate and doxorubicin) during the heat
polymerization of cement. Wasserlauf and colleauges10
demonstrated that cement pellets released these drugs
slowly for up to 6 months in vitro; the release was greater
in the first few days, rapidly declining with time. In in vivo,
high levels of the drugs were recovered from blood drained
from the operative wound of the rabbits, while very low
levels of these drugs were found in the serum.14
According to previous studies, anti-neoplastic drug-
loaded cement may be effective in the treatment of local
tumor surgery and the improved delivery method may
reduce the side effects that result from systemic adminis-
tration of such drugs.14 As an adjuvant treatment, we used
combined cement to fill the bone defect created by exci-
sion of the tumor and to release a local, high, and sustained
concentration of antineoplastic agent to prevent the risk of
recurrence. The drugs that were chosen are commonly used
in the treatment of tumors frequently associated with bony
metastases.11 Since the tumor was gynecologic in origin, we
selected cisplatin as our regimen of choice. In this case,
40 mg of cement blended with 30 ml of cisplatin prolonged
the solid phase, but the solid cement remained in steady
state.
Synchronous primary cancers of the ovary and endo-
metrium have been reported in about 5 percent of women.
There are only a few case reports describing bone metas-
tasis in each cancer. The risk factors and clinical outcome
of women with synchronous primary cancers differ with
different histologic findings of the ovarian tumor. With the
endometrioid/serous type, the prognosis did not seem
favorable.15 Therefore, we used phenol cauterization and
massive normal saline irrigation in the confined cavity to
prevent tumor seeding. Cisplatin-loaded cement was alsoapplied, and adjuvant radiotherapy administered to
reduce local recurrence. Although it is difficult to evaluate
the effect of cisplatin-loaded cement, we believe it is
beneficial for a patient, especially one with an advanced
cancer that may be resistant to radiotherapy. It will be
desirable to accumulate more cases for further research.
However, it is worth noting that this method might be
contraindicated in a patient with pathologic fracture that
requires en bloc surgery.
4. Conclusion
A woman 39 years of age was diagnosed with acetabular
metastasis and we treated her with minimal-injury surgery
with preservation of the hip joint. In this case, cisplatin-
loaded cement filling after curettage of the malignant
periacetabular tumor proved to be a safe method. The
advantages of the treatment include rapid rehabilitation,
a short hospital stay, and favorable functional results with
independent ambulation. This method appears to be an
acceptable option in certain patients with periacetabular
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